MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-019-0684-5

Медицинская библиотека · Leukemia · 2020

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Kinstrie Ross, Horne Gillian A, Morrison Heather, Irvine David, Munje Chinmay, Castañeda Eduardo Gómez, Moka Hothri A, Dunn Karen, Cassels Jennifer E, Parry Narissa, Clarke Cassie J, Scott Mary T, Clark Richard E, Holyoake Tessa L, Wheadon Helen, Copland Mhairi

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite targeted therapeutic approaches, BCR-ABL-independent mechanisms exist which sustain the survival of leukemic stem cells (LSCs). Although other markers of a primitive CML LSC population have been identified in the preclinical setting, only CD26 appears to offer clinical utility. Here we demonstrate consistent and selective expression of CD93 on a lin-CD34+CD38-CD90+ CML LSC population and show in vitro and in vivo data to suggest increased stem cell characteristics, as well as robust engraftment in patient-derived xenograft models in comparison with a CD93- CML stem/progenitor cell population, which fails to engraft. Through bulk and single-cell analyses of selected stem cell and cell survival-specific genes, we confirmed the quiescent character and demonstrate their persistence in a population of CML patient samples who demonstrate molecular relapse on TKI withdrawal. Taken together, our results identify that CD93 is consistently and selectively expressed on a lin-CD34+CD38-CD90+ CML LSC population with stem cell characteristics and may be an important indicator in determining poor TKI responders.

Для цитирования: Kinstrie Ross, Horne Gillian A, Morrison Heather, Irvine David, Munje Chinmay, Castañeda Eduardo Gómez, Moka Hothri A, Dunn Karen, Cassels Jennifer E, Parry Narissa, Clarke Cassie J, Scott Mary T, Clark Richard E, Holyoake Tessa L, Wheadon Helen, Copland Mhairi. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.. Leukemia. 2020. DOI: 10.1038/s41375-019-0684-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.